Zaslavskaia R M, Buniatian N D, Sergeev S V, Lednev O A
Klin Med (Mosk). 2009;87(10):61-2.
The study included 20 patients aged 61-86 (mean 73.1 +/- 3.1) years with stage II hypertensive disease, type 2 diabetes and nephropathy with signs of grade I chronic renal insufficiency (CRI). The major parameters measured were AP, HR, laboratory characteristics of carbohydrate metabolism and renal function. Prestarium given at a dose of 4 mg BID had not only antihypertensive but also negative chronotropic effect, decreased energy consumption by myocardium, and normalized daily AP profile (24 hr AP monitoring). Adequate control of diabetes ensured close-to-normal carbohydrate metabolism. Prestarium therapy did not cause further aggravation of renal insufficiency in patients with grade I CRI, nor did it alter creatinine and urea levels.
该研究纳入了20例年龄在61 - 86岁（平均73.1±3.1岁）的患者，这些患者患有II期高血压病、2型糖尿病和伴有I级慢性肾功能不全（CRI）体征的肾病。所测量的主要参数为动脉压（AP）、心率（HR）、碳水化合物代谢的实验室指标和肾功能。以每日两次、每次4毫克的剂量给予普瑞斯塔姆，不仅具有降压作用，还具有负性变时作用，可降低心肌能量消耗，并使每日动脉压曲线正常化（24小时动脉压监测）。对糖尿病的充分控制确保了碳水化合物代谢接近正常。普瑞斯塔姆治疗并未导致I级CRI患者的肾功能不全进一步加重，也未改变肌酐和尿素水平。
